✨ Your Portfolio is fetched and updated from zerodha.
Nano Miscellaneous

Checkpoint Trends Ltd.

CHECKPOINT

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹45 Cr.
P/E
30.60

Checkpoint Trends Ltd.

  • Rubra Medicaments
  • Jaihind Synthetics
  • Khyati Global Vent

FAQs on Checkpoint Trends Ltd. Shareprice

Rubra Medicaments has given better returns compared to its competitors.
Rubra Medicaments has grown at ~491.72% over the last 1yrs while peers have grown at a median rate of 14.16%

Rubra Medicaments is not expensive.
Latest PE of Rubra Medicaments is 30.6, while 3 year average PE is 132.
Also latest EV/EBITDA of Rubra Medicaments is 23.12 while 3yr average is 89.43.

View FAQ's On Business

Growth Table

  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Balance Sheet

  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Cash Flow

  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Quarterly Results

  • Checkpoint Trends Ltd.
  • Jaihind Synthetics
  • Khyati Global Vent

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Checkpoint Trends Ltd. Financials

Balance sheet of Rubra Medicaments is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Rubra Medicaments is decreasing.
Latest net debt of Rubra Medicaments is -₹0.13 Crs as of Sep-25.
This is less than Mar-25 when it was -₹0.05 Crs.

The profit is oscillating.
The profit of Rubra Medicaments is ₹1.46 Crs for TTM, ₹0.03 Crs for Mar 2025 and ₹0.03 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Rubra Medicaments latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech